Strategies to Optimize Antiretroviral Therapy Services for Maternal & Child Health: the MCH-ART Study

This study includes a three-phase design in which HIV-positive pregnant women are followed during the antenatal and postnatal periods. Throughout, participants will attend study measurement visits conducted separately from routine ART service appointments.

Phase 1 is a cross-sectional evaluation of consecutive HIV-infected pregnant women attending their first antenatal clinic visit seeking care at the study clinic. This phase of the study will allow characterization of the health status of the population of HIV-positive pregnant women seeking care at the Gugulethu (Midwife Obstetric Unit)MOU and the services they receive. At their first antenatal clinic visit, women will be approached to complete Informed Consent #1, including consent for abstraction of routine clinic data on obstetric and HIV-related care. As part of this cross-sectional study, participating women will complete a short questionnaire and undergo phlebotomy.

Phase 2 of the study is an observational cohort of all women who are eligible for initiation of lifelong antiretroviral therapy (following SA guidelines), from their second antenatal clinic visit until their first postpartum clinic visit (conducted within 7 days postpartum). This phase of the study will provide detailed description of ART initiation and antenatal follow-up in the population of women who will be involved in the postnatal component of the study, and be used to measure potential predictors of the primary outcome. At the second antenatal clinic visit, women from Phase 1 who are ART-eligible or who initiated ART during the pregnancy will be approached to complete Informed Consent #2, be interviewed with questionnaire on behavioral and psychosocial measures, and undergo phlebotomy. Women will complete another study measurement visit during the third trimester and again within 1 week postpartum (with study measurement visits timed to coincide with routine care appointments). At these visits, additional questionnaires and phlebotomy will be used to collect study measures.

Phase 3 of the study is a randomised trial of strategies for delivering ART to women during the postpartum period (the primary objective) with measurement of secondary outcomes during the postnatal period. Women enrolled in Phase 2 who are breastfeeding their infants will be approached to participate in the trial at the routine postpartum clinic visit (this takes place within 7 days of birth and is the only standard postpartum care for women). After completing Informed Consent #3, women will be interviewed with behavioral and psychosocial questionnaires and undergo phlebotomy for study measurements before randomization.

Randomization will be to one of two approaches to providing ART during the postpartum period to HIV-infected mothers who are breastfeeding:

• Arm A: referral to general adult ART services from approximately 4-8 weeks postpartum (the local standard of care)
• Arm B: continued receipt of ART in the antenatal clinic, as part of a MCH-focused ART service that includes primary care for HIV-exposed infants. This service only refers women to general adult ART services after the end of breastfeeding and once infants' final HIV status is determined

Women randomized to Arm A or Arm B will be asked to return for four additional study visits during the postpartum period at approximately 6 weeks, 6 months, 9 months and 12 months postpartum. Details of study measurement visits conducted in both the antenatal and postnatal periods are described below in Section 8.

For women enrolled in Phases 1 and 2 of the study, participation will not impact on any aspect of routine antenatal and obstetric care during pregnancy. Similarly, throughout the antenatal period women's HIV-related care (including PMTCT services and ART) will not be affected in any way by participation, with ART initiated according to the current standard of care. For women enrolled in Phase 3 of the study, participation will only impact on the setting and approach to providing ART services to mothers during the postpartum period, comparing immediate referral to general adult ART services versus ongoing care in MCH-focused ART services within the Gugulethu MOU.

Overall, a total of approximately 1600 HIV+ pregnant women will participate in Phase 1 of the study over 12 months. From this group, it is anticipated that approximately 400-500 HIV+ pregnant women eligible for ART will be identified as eligible for Phase 2 participation. We estimate that of the approximately 600 women on ART followed in Phase 2, approximately 480 will be eligible for and enrolled into Phase 3 and randomized to one of two postpartum ART delivery strategies.

Follow-up of all participants in Phase 3 will end at 12 months postpartum. The total length of participation will vary based on gestational age at enrollment into Phase 2, ranging from a minimum of approximately 52 weeks to a maximum of approximately 80 weeks.

Inclusion criteria

Phase 1

• Age 18 years or older
• Documented HIV-infection according to two finger-prick rapid tests using different test types (per routine protocol in this setting) or documentation of HIV status for those women self reporting HIV diagnosis.
• Confirmed pregnancy according to urine pregnancy test, ultrasound or clinical assessment
• Able to provide informed consent for research (Informed Consent #1)

Phase 2: Subset of Phase 1 participants who are ART-eligible

• Consented and participated in Phase 1
• Documented ART eligibility based on CD4 count and/or WHO staging according to public sector testing or assessment
• Not currently using triple-drug antiretroviral therapy (women started on AZT for PMTCT during the current pregnancy are eligible) or have not used ART within the previous 6 months.
• Able to provide informed consent for research (Informed Consent #2)

Phase 3: Subset of Phase 2 participants eligible for randomization

• Consented and participated in Phase 2
• Initiated ART during the antenatal period
• Currently breastfeeding within <7 days postpartum (with an allowable window of up to 28 days postpartum)
• Willingness to be randomized and return for postnatal study visits
• Able to provide informed consent for research (Informed Consent #

Exclusion criteria

Individuals meeting any of the following exclusion criteria at the point in the study will be excluded:

• Not currently pregnant (Phases 1 and 2) or loss of pregnancy/neonate (Phase 3) at the time of eligibility determination
• Intention to relocate out of Cape Town permanently during the study period (Phase 2 and 3 only)
• Any medical, psychiatric or social condition which in the opinion of the investigators would affect the ability to consent and/or participate in the study (all phases), including:

• Refusal to take ART/ARVs
• Denial of HIV status